干细胞来源生物性心室辅助组织治疗心力衰竭
这项开放标签1-2期研究评估了同种异体诱导多能干细胞来源的心肌细胞和基质细胞构建的工程心肌(BioVAT)移植用于心脏再肌化。20例左室射血分数≤35%且至少1个左室节段运动减弱或无运动的心衰患者接受5、10或20个工程心肌单位的BioVAT移植,均接受免疫抑制。在20个工程心肌单位的安全最大剂量组中,12例完成预设3个月中期随访,靶壁厚度最小二乘均值增加4.5 mm(90%CI 3.7-5.4,P<0.001),左室射血分数增加3.9个百分点(90%CI 0.9-6.8,P=0.04),KCCQ-OSS增加6.7分(90%CI 1.0-12.5,P=0.06)。所有患者均发生至少1起不良事件,3例死亡,1例心脏移植,作者认为需要更长期随访和进一步临床研究。
要点
- 20例左室射血分数≤35%且至少1个左室节段运动减弱或无运动的心衰患者接受BioVAT移植,均接受免疫抑制。
- 接受20个工程心肌单位安全最大剂量的16例中,12例完成预设3个月中期随访,靶壁厚度最小二乘均值增加4.5 mm(90%CI 3.7-5.4,P<0.001)。
- 同一12例中左室射血分数增加3.9个百分点(90%CI 0.9-6.8,P=0.04),KCCQ-OSS增加6.7分(90%CI 1.0-12.5,P=0.06)。
- 所有患者均发生至少1起不良事件;3例死亡(血管麻痹、新型冠状病毒感染、主动脉夹层各1例),1例接受心脏移植。
- 4例因植入左心室辅助装置(2例)、肾功能衰竭(1例)、尿路上皮癌(1例)而停用免疫抑制。
适用人群与场景
- 心力衰竭且左室射血分数≤35%、至少1个左室节段运动减弱或无运动的患者。
- 研究为开放标签1-2期研究,患者接受5、10或20个工程心肌单位的BioVAT同种异体移植物,均接受免疫抑制。
诊断标准与关键阈值
- 左室射血分数≤35%,且至少1个左室节段运动减弱或无运动。
处置流程与药物剂量
- BioVAT同种异体移植物由5、10或20个工程心肌单位组成,所有患者接受免疫抑制。
- 4例停用免疫抑制,原因分别为植入左心室辅助装置(2例)、肾功能衰竭(1例)、尿路上皮癌(1例)。
研究设计与关键结果
- 开放标签1-2期研究,共20例患者接受治疗;3例死亡(血管麻痹、新型冠状病毒感染、主动脉夹层各1例),1例接受心脏移植。
- 接受20个工程心肌单位安全最大剂量的16例中,12例完成预设3个月中期随访。
- 12例完成随访者靶壁厚度最小二乘均值增加4.5 mm(90%CI 3.7-5.4,P<0.001)。
- 12例完成随访者左室射血分数增加3.9个百分点(90%CI 0.9-6.8,P=0.04)。
- 12例完成随访者KCCQ-OSS增加6.7分(90%CI 1.0-12.5,P=0.06)。
- 所有患者均发生至少1起不良事件。
证据类型、等级与局限
- 证据类型:开放标签1-2期研究。
- 局限:作者指出需要更长期随访和进一步临床研究。
对床旁实践的改变
- 作者认为,BioVAT心脏再肌化与3个月时靶壁厚度、左室射血分数和KCCQ-OSS增加相关,所有患者均发生至少1起不良事件,需要更长期随访和进一步临床研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Biologic ventricular assist tissue (BioVAT) is formulated from engineered heart muscle composed of cardiomyocytes and stromal cells derived from allogeneic induced pluripotent stem cells for cardiac remuscularization in patients with heart failure and a reduced left ventricular ejection fraction.
METHODS: We conducted an open-label, phase 1-2 study of tissue-engineered heart repair by means of BioVAT transplantation. Patients with heart failure and a left ventricular ejection fraction of 35% or less and at least one hypokinetic or dyskinetic left ventricular segment were treated with BioVAT allografts, which consisted of 5, 10, or 20 engineered-heart-muscle units. All the patients received immunosuppression. Safety was assessed as adverse events related to the procedure. The primary efficacy end points were the change from baseline in the target heart-wall thickness, the left ventricular ejection fraction, and the Kansas City Cardiomyopathy Questionnaire-Overall Summary Score (KCCQ-OSS).
RESULTS: A total of 20 patients were treated in the study. Three patients died during the study (1 each from vasoplegia, coronavirus disease 2019, and aortic dissection). One patient underwent heart transplantation. Immunosuppression was discontinued in 4 patients because of implantation of a left ventricular assist device (in 2 patients), renal failure (in 1 patient), and urothelial carcinoma (in 1 patient). Of the 16 patients who were treated with the safe maximal dose (20 engineered-heart-muscle units), 12 patients completed the prespecified 3-month interim follow-up. The least-squares mean increase in the target-wall thickness was 4.5 mm (90% confidence interval [CI], 3.7 to 5.4; P<0.001), the increase in the left ventricular ejection fraction was 3.9 percentage points (90% CI, 0.9 to 6.8; P = 0.04), and the increase in the KCCQ-OSS was 6.7 points (90% CI, 1.0 to 12.5; P = 0.06). All the patients had at least one adverse event.
CONCLUSIONS: In this interim analysis, cardiac remuscularization with BioVAT was associated with an increase in the target heart-wall thickness, left ventricular ejection fraction, and KCCQ-OSS at 3 months; all the patients had at least one adverse event. Longer-term follow-up and further clinical investigation are warranted. (Funded by the German Center for Cardiovascular Research and Repairon; BioVAT-HF ClinicalTrials.gov number, NCT04396899.).
参考来源
- Zimmermann WH, Ensminger S, Kutschka I, et al. Stem-Cell-Derived Biologic Ventricular Assist Tissue in Heart Failure. N Engl J Med. 2026. PMID: 42202318. doi:10.1056/NEJMoa2513525
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。